Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Back to Jobs

OTIVIDEX ® Phase 3 trial results in Ménière’s disease expected by end of February OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with

Apply Now